Bioxytran, Inc.
BIXT
$0.04
$0.000.84%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 22.04% | 298.39% | |||
| Depreciation & Amortization | -30.95% | 68.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.99% | 120.74% | |||
| Operating Income | -21.99% | -120.74% | |||
| Income Before Tax | -84.72% | -898.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -84.72% | -898.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -84.72% | -898.59% | |||
| EBIT | -21.99% | -120.74% | |||
| EBITDA | -22.44% | -121.33% | |||
| EPS Basic | -62.50% | -900.00% | |||
| Normalized Basic EPS | -105.00% | -1,100.00% | |||
| EPS Diluted | -62.50% | -900.00% | |||
| Normalized Diluted EPS | -105.00% | -1,100.00% | |||
| Average Basic Shares Outstanding | 12.98% | 0.17% | |||
| Average Diluted Shares Outstanding | 12.98% | 0.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||